

Friedhelm Raue

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6080501/friedhelm-raue-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218
papers

9,112
citations

44
h-index

90
g-index

281
ext. papers

10,237
ext. citations

4.4
avg, IF

5.51
L-index

#	Paper	IF	Citations
218	Guidelines for diagnosis and therapy of MEN type 1 and type 2. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 5658-71	5.6	1466
217	Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. <i>Thyroid</i> , 2015 , 25, 567-610	6.2	1191
216	Early malignant progression of hereditary medullary thyroid cancer. <i>New England Journal of Medicine</i> , 2003 , 349, 1517-25	59.2	408
215	The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. <i>JAMA - Journal of the American Medical Association</i> , 1996 , 276, 1575-9	27.4	233
214	Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. <i>Journal of Internal Medicine</i> , 1995 , 238, 343-6	10.8	218
213	A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 770-4	5.6	194
212	A study of complaints and their relation to vertebral destruction in patients with osteoporosis. <i>Bone and Mineral</i> , 1990 , 8, 217-29		161
211	Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. <i>Clinical Endocrinology</i> , 1995 , 43, 123-7	3.4	143
210	Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. <i>Genes Chromosomes and Cancer</i> , 1995 , 12, 209-12	5	135
209	External radiotherapy of pituitary adenomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995 , 33, 307-14	4	129
208	Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. <i>Oncogene</i> , 1999 , 18, 1369-73	9.2	117
207	Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. <i>European Journal of Endocrinology</i> , 2006 , 155, 229-36	6.5	110
206	Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. <i>The Clinical Investigator</i> , 1993 , 71, 7-12		109
205	Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. <i>International Journal of Cancer</i> , 2001 , 95, 62-6	7.5	106
204	Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996 , 81, 1780-3	5.6	102
203	Update multiple endocrine neoplasia type 2. <i>Familial Cancer</i> , 2010 , 9, 449-57	3	101
202	Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. <i>Cancer Research</i> , 1996 , 56, 2167-70	10.1	101

201	Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. <i>Journal of Internal Medicine</i> , 1995 , 238, 369-73	10.8	100
200	Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. <i>Human Mutation</i> , 2011 , 32, 51-8	4.7	98
199	Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2004 , 112, 52-8	2.3	97
198	Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2007 , 157, 215-20	6.5	90
197	Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC. <i>Molecular and Cellular Endocrinology</i> , 2010 , 322, 2-7	4.4	85
196	Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998 , 25, 424-30	8.8	83
195	Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. <i>Journal of Cancer Research and Clinical Oncology</i> , 1990 , 116, 21-3	4.9	82
194	Multiple Endocrine Neoplasia Type 2: Clinical Features and Screening. <i>Endocrinology and Metabolism Clinics of North America</i> , 1994 , 23, 137-156	5.5	77
193	Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. <i>Clinical Endocrinology</i> , 2007 , 67, 613-22	3.4	74
192	Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma. <i>Thyroid</i> , 2013 , 23, 294-300	6.2	72
191	Multiple endocrine neoplasia type 2. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2010 , 24, 371-87	6.5	68
190	Activating mutations in the calcium-sensing receptor: genetic and clinical spectrum in 25 patients with autosomal dominant hypocalcaemia - a German survey. <i>Clinical Endocrinology</i> , 2011 , 75, 760-5	3.4	65
189	Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. <i>Clinical Chemistry</i> , 2011 , 57, 467-74	5.5	63
188	Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium. <i>European Journal of Endocrinology</i> , 2013 , 168, 307-14	6.5	62
187	Novel inactivating mutations of the calcium-sensing receptor: the calcimimetic NPS R-568 improves signal transduction of mutant receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 4797-803	5.6	62
186	Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. <i>Hormones</i> , 2009 , 8, 23-8	3.1	61
185	Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. <i>Thyroid</i> , 1992 , 2, 113-7	6.2	60
184	Somatostatin receptor imaging in persistent medullary thyroid carcinoma. <i>Clinical Endocrinology</i> , 1995 , 42, 31-7	3.4	59

183	Increased prevalence of colonic adenomas in patients with acromegaly. <i>European Journal of Endocrinology</i> , 1994 , 131, 235-7	6.5	57
182	German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2. <i>Langenbeck's Archives of Surgery</i> , 1998 , 383, 334-6	3.4	55
181	Parathyroid hormone-related peptide and 8701-BC breast cancer cell growth and invasion in vitro: evidence for growth-inhibiting and invasion-promoting effects. <i>Molecular and Cellular Endocrinology</i> , 1995 , 111, 225-32	4.4	55
180	Genotype-phenotype correlation in multiple endocrine neoplasia type 2. <i>Clinics</i> , 2012 , 67 Suppl 1, 69-75	2.3	54
179	Response to methimazole in Graves disease. The European Multicenter Study Group. <i>Clinical Endocrinology</i> , 1995 , 43, 257-63	3.4	53
178	Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma. Three-year results. <i>Cancer</i> , 1993 , 72, 3685-93	6.4	53
177	Novel activating mutations of the calcium-sensing receptor: the calcilytic NPS-2143 mitigates excessive signal transduction of mutant receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, E229-33	5.6	48
176	Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. <i>Clinical Endocrinology</i> , 2008 , 69, 259-63	3.4	48
175	Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993 , 76, 801-3	5.6	44
174	Performance evaluation of automated assays for beta-CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIROSE Multicenter Study). <i>Clinical Chemistry and Laboratory Medicine</i> , 2004 , 42, 90-5	5.9	43
173	Inactivating calcium-sensing receptor mutations in patients with primary hyperparathyroidism. <i>Clinical Endocrinology</i> , 2011 , 75, 50-5	3.4	42
172	Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. <i>Surgery</i> , 1995 , 118, 1099-103; discussion 1103-4	3.6	42
171	Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007 , 115, 509-17	2.3	41
170	Changing Concepts in the Management of Hereditary and Sporadic Medullary Thyroid Carcinoma. <i>Endocrinology and Metabolism Clinics of North America</i> , 1990 , 19, 613-635	5.5	40
169	Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation. <i>Recent Results in Cancer Research</i> , 2015 , 204, 139-56	1.5	39
168	Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation. <i>Endocrine-Related Cancer</i> , 2008 , 15, 1035-41	5.7	39
167	Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2008 , 158, 811-6	6.5	36
166	Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1998 , 106, 353-9	2.3	36

165	Synaptophysin identified in metastases of neuroendocrine tumors by immunocytochemistry and immunoblotting. <i>American Journal of Clinical Pathology</i> , 1987 , 88, 560-9	1.9	36
164	The hypercalcaemic syndrome in rats bearing the Walker carcinosarcoma 256. <i>European Journal of Endocrinology</i> , 1975 , 78, 613-24	6.5	35
163	Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2-relevance of specific mutations in the RET proto-oncogene. <i>European Journal of Endocrinology</i> , 1996 , 135, 222-5	6.5	34
162	Circulating levels of midregional parathyroid hormone-related protein in hypercalcaemia of malignancy. <i>Clinical Endocrinology</i> , 1992 , 37, 290-7	3.4	34
161	Chromogranin A as tumor marker in medullary thyroid carcinoma. <i>Thyroid</i> , 1992 , 2, 5-10	6.2	33
160	Multiple endocrine neoplasia type 2: 2007 update. <i>Hormone Research in Paediatrics</i> , 2007 , 68 Suppl 5, 101-4	3.3	31
159	Papillary carcinoma in an ectopic thyroid. <i>Hormone Research</i> , 1991 , 35, 86-8		31
158	Reversible diminished calcitonin secretion in the rat during chronic hypercalcemia. <i>Endocrinology</i> , 1984 , 115, 2362-7	4.8	30
157	Clinical significance of antibodies against calcitonin. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1995 , 103, 345-51	2.3	29
156	Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma. <i>Recent Results in Cancer Research</i> , 2015 , 204, 61-90	1.5	28
155	The role of the extracellular calcium-sensing receptor in health and disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2006 , 114, 397-405	2.3	28
154	Early diagnosis of the multiple endocrine neoplasia type 2 syndrome: consensus statement. European Community Concerted Action: Medullary Thyroid Carcinoma. <i>European Journal of Clinical Investigation</i> , 1992 , 22, 755-60	4.6	28
153	CDC73-related hereditary hyperparathyroidism: five new mutations and the clinical spectrum. <i>European Journal of Endocrinology</i> , 2011 , 165, 477-83	6.5	27
152	Regulation of calcitonin gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. <i>Journal of Bone and Mineral Research</i> , 1992 , 7, 1233-7	6.3	26
151	Coincidence of multiple endocrine neoplasia types 1 and 2: mutations in the RET protooncogene and MEN1 tumor suppressor gene in a family presenting with recurrent primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 4063-7	5.6	26
150	Heterozygous inactivating CaSR mutations causing neonatal hyperparathyroidism: function, inheritance and phenotype. <i>European Journal of Endocrinology</i> , 2016 , 175, 421-31	6.5	26
149	Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma. <i>Journal of the Endocrine Society</i> , 2018 , 2, 933-943	0.4	25
148	Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer. <i>Clinical Endocrinology</i> , 2012 , 76, 691-7	3.4	25

147	Down-regulation of calcitonin receptors in T47D cells by internalization of calcitonin-receptor complexes. <i>Molecular and Cellular Endocrinology</i> , 1988 , 58, 9-15	4.4	25
146	Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary?. <i>World Journal of Surgery</i> , 2017 , 41, 2026-2032	3.3	24
145	Change in the spectrum of RET mutations diagnosed between 1994 and 2006. <i>Clinical Laboratory</i> , 2007 , 53, 273-82	2	24
144	Severe form of thyroid hormone resistance in a patient with homozygous/hemizygous mutation of T3 receptor gene. <i>European Journal of Endocrinology</i> , 2004 , 150, 819-23	6.5	23
143	In vitro detection of neutralizing antibodies after treatment of Paget disease of bone with nasal salmon calcitonin. <i>Journal of Bone and Mineral Research</i> , 1990 , 5, 387-91	6.3	23
142	Long-Term Follow-up in Medullary Thyroid Carcinoma. <i>Recent Results in Cancer Research</i> , 2015 , 204, 207-25	2.5	21
141	Long-Term Survivorship in Multiple Endocrine Neoplasia Type 2B Diagnosed Before and in the New Millennium. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 235-243	5.6	21
140	Amino alcohol- (NPS-2143) and quinazolinone-derived calcilytics (ATF936 and AXT914) differentially mitigate excessive signalling of calcium-sensing receptor mutants causing Bartter syndrome Type 5 and autosomal dominant hypocalcemia. <i>PLoS ONE</i> , 2014 , 9, e115178	3.7	21
139	New operative strategy in the treatment of metastasizing medullary carcinoma of the thyroid. <i>European Journal of Surgical Oncology</i> , 1990 , 16, 366-9	3.6	21
138	United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for Calcitonin. <i>Clinical Chemistry</i> , 2017 , 63, 1489-1496	5.5	20
137	Hypercalcitoninaemia in patients with pheochromocytoma. <i>Klinische Wochenschrift</i> , 1978 , 56, 697-701		20
136	Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades. <i>Clinical Endocrinology</i> , 2017 , 87, 320-326	3.4	19
135	Are commonly recommended dosages for vitamin D supplementation too low? Vitamin D status and effects of supplementation on serum 25-hydroxyvitamin D levels--an observational study during clinical practice conditions. <i>Osteoporosis International</i> , 2011 , 22, 231-40	5.3	19
134	Mutational analysis of the PHEX gene: novel point mutations and detection of large deletions by MLPA in patients with X-linked hypophosphatemic rickets. <i>Calcified Tissue International</i> , 2009 , 85, 211-20 ^{3.9}	3.9	19
133	Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation. <i>Surgery</i> , 2004 , 136, 1083-7	3.6	19
132	Clinical features of multiple endocrine neoplasia type 1 and type 2. <i>Hormone Research</i> , 1992 , 38 Suppl 2, 31-5		19
131	Rhythmic oscillations of cytosolic free calcium in rat C-cells. <i>Molecular and Cellular Endocrinology</i> , 1989 , 64, 267-70	4.4	19
130	Calcitonin in human pathophysiology. <i>Hormone Research</i> , 1984 , 20, 65-73		19

129	The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases. <i>Archives of Internal Medicine</i> , 1992 , 152, 1250-2		19
128	Neutralizing antibodies against calcitonin. <i>Hormone and Metabolic Research</i> , 1993 , 25, 486-8	3.1	18
127	Norepinephrine induced calcitonin secretion in rat medullary thyroid carcinoma 6-23 cells: interaction between intracellular calcium and cAMP. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1996 , 104, 43-9	2.3	17
126	Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955. <i>Hormone and Metabolic Research</i> , 1993 , 25, 40-4	3.1	17
125	Homologous radioimmunoassay for human parathyrin (residues 53-84).. <i>Clinical Chemistry</i> , 1982 , 28, 1749-51	3.1	17
124	Formation of neutralizing antibodies after treatment with human calcitonin. <i>American Journal of Medicine</i> , 1993 , 95, 439-42	2.4	16
123	Long-term excess of endogenous calcitonin in patients with medullary thyroid carcinoma does not affect bone mineral density. <i>Journal of Endocrinology</i> , 1992 , 134, 141-7	4.7	16
122	Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. <i>Thyroid</i> , 2021 , 31, 459-469	6.2	16
121	Rapid response to sorafenib in metastatic medullary thyroid carcinoma. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2011 , 119, 151-5	2.3	15
120	Microsurgical neck dissection for metastasizing medullary thyroid carcinoma. <i>European Journal of Surgical Oncology</i> , 1995 , 21, 195-7	3.6	15
119	The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma. <i>Nuclear Medicine Communications</i> , 1993 , 14, 439-45	1.6	15
118	Inhibition of Ca(2+)-induced calcitonin secretion by somatostatin: roles of voltage dependent Ca2+ channels and G-proteins. <i>Cellular Signalling</i> , 1992 , 4, 77-85	4.9	15
117	Cyclic AMP formation in rat bone and kidney cells is stimulated equally by parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1993 , 101, 150-5	2.3	14
116	Reversible desensitization of calcitonin secretion by repetitive stimulation with calcium. <i>Molecular and Cellular Endocrinology</i> , 1989 , 63, 263-6	4.4	14
115	Prophylactic thyroidectomy in MEN IIA: does the calcitonin level correlate with tumor spread?. <i>Langenbecks Archiv Fur Chirurgie</i> , 1998 , 383, 170-3		13
114	Tumor necrosis factor alpha inhibits the stimulatory effect of the parathyroid hormone-related protein on cyclic AMP formation in osteoblast-like cells via protein kinase C+. <i>Biochemical and Biophysical Research Communications</i> , 1992 , 182, 341-7	3.4	13
113	Role of voltage-dependent calcium channels in secretion of calcitonin from human medullary thyroid carcinoma cells. <i>Klinische Wochenschrift</i> , 1989 , 67, 635-9		13
112	Multiple endocrine neoplasia type 2. Clinical features and screening. <i>Endocrinology and Metabolism Clinics of North America</i> , 1994 , 23, 137-56	5.5	13

111	New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2010 , 118, 550-3	2.3	12
110	Increased incidence of cardiovascular diseases in primary hyperparathyroidism--a cause for more aggressive treatment?. <i>European Journal of Clinical Investigation</i> , 1998 , 28, 277-8	4.6	12
109	Routine calcitonin determination in thyroid nodules--an effective approach?. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1998 , 106, 289-91	2.3	12
108	Glucocorticoids decrease the production of parathyroid hormone-related protein in vitro but not in vivo in the Walker carcinosarcoma 256 rat model. <i>Bone</i> , 1996 , 18, 315-9	4.7	12
107	KBberling-Dunnigan syndrome: a rare cause of generalized muscular hypertrophy. <i>Muscle and Nerve</i> , 1996 , 19, 843-7	3.4	12
106	Medullary Thyroid Carcinoma: Imaging. <i>Recent Results in Cancer Research</i> , 2015 , 204, 91-116	1.5	11
105	Multiple endocrine neoplasia type 2 (MEN 2). <i>European Journal of Cancer</i> , 2009 , 45 Suppl 1, 267-73	7.5	11
104	A new in vitro bioassay for human calcitonin: validation and comparison to the rat hypocalcemia bioassay. <i>Bone and Mineral</i> , 1992 , 17, 65-74		11
103	Action of calcitonin gene-related peptide at the calcitonin receptor of the T47D cell line. <i>Hormone and Metabolic Research</i> , 1987 , 19, 563-4	3.1	11
102	Radioimmunoassay for human parathyroid hormone for differentiation between patients with hypoparathyroidism, hyperparathyroidism and normals. <i>Hormone and Metabolic Research</i> , 1979 , 11, 375-8	3.1	11
101	Long-Term Outcomes and Aggressiveness of Hereditary Medullary Thyroid Carcinoma: 40 Years of Experience at One Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 4264-4272	5.6	10
100	Chemotherapie bei Schilddrßenkarzinomen: Indikation und Ergebnisse. <i>Onkologe</i> , 1997 , 3, 55-58	0.1	10
99	Extracellular calcium sensitivity and voltage-dependent calcium channels in C cells. <i>Endocrine Reviews</i> , 1995 , 16, 752-64	27.2	10
98	Evaluation of sensitive PDN-21 (katakalcin) determination as tumor marker in medullary thyroid carcinoma. <i>Journal of Endocrinological Investigation</i> , 1992 , 15, 93-8	5.2	10
97	Inhibitory effect of somatostatin on cAMP accumulation and calcitonin secretion in C-cells: involvement of pertussis toxin-sensitive G-proteins. <i>Molecular and Cellular Endocrinology</i> , 1992 , 86, 213-9	4.4	10
96	Acute effect of 1,25-dihydroxy-vitamin D3 on calcitonin secretion in rats. <i>Hormone and Metabolic Research</i> , 1983 , 15, 208-9	3.1	10
95	Long-Term Follow-Up and Treatment of Postoperative Permanent Hypoparathyroidism in Patients with Medullary Thyroid Carcinoma: Differences in Complete and Partial Disease. <i>Hormone and Metabolic Research</i> , 2016 , 48, 806-813	3.1	9
94	Results and follow-up in eleven MEN 2A gene carriers after prophylactic thyroidectomy. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1997 , 105 Suppl 4, 76-8	2.3	9

93	Regulation of calcitonin secretion in vitro. <i>Hormone and Metabolic Research</i> , 1993 , 25, 473-6	3.1	9
92	Superior local tolerability of human versus salmon calcitonin preparations in young healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 1991 , 41, 211-5	2.8	9
91	Levels of parathyroid hormone-related protein in hypercalcemia of malignancy: comparison of midregional radioimmunoassay and two-site immunoradiometric assay. <i>The Clinical Investigator</i> , 1993 , 71, 31-6		9
90	Neuron-specific enolase in medullary thyroid carcinoma: immunohistochemical demonstration, but no significance as serum tumor marker. <i>Journal of Cancer Research and Clinical Oncology</i> , 1987 , 113, 599-602	4.0	9
89	Importance of ultrasound examination for the follow-up of medullary thyroid carcinoma: comparison with other localization methods. <i>Henry Ford Hospital Medical Journal</i> , 1987 , 35, 122-3		9
88	Effects of passive immunization against parathyroid hormone-related protein: PTHrP is the responsible factor in mediating hypercalcemia in the Walker carcinosarcoma 256 rat model. <i>Journal of Bone and Mineral Research</i> , 1995 , 10, 7-16	6.3	8
87	Application of genetic screening in families with hereditary medullary thyroid carcinoma. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1996 , 104 Suppl 4, 108-10	2.3	8
86	Presymptomatic genetic screening in families with multiple endocrine neoplasia type 2. <i>Journal of Molecular Medicine</i> , 1995 , 73, 229-33	5.5	8
85	1,25-Dihydroxyvitamin D3 suppresses dexamethasone effects on calcitonin secretion. <i>Molecular and Cellular Endocrinology</i> , 1990 , 71, R13-8	4.4	8
84	Enhanced calcitonin secretion in the rat after parathyroidectomy and during chronic calcium deprivation. <i>European Journal of Clinical Investigation</i> , 1988 , 18, 284-9	4.6	8
83	Importance of early diagnosis and follow-up in multiple endocrine neoplasia (MEN II B). <i>European Journal of Pediatrics</i> , 1984 , 143, 112-6	4.1	8
82	Epidemiological aspects of hypercalcemia of malignancy. <i>Recent Results in Cancer Research</i> , 1994 , 137, 99-106	1.5	8
81	Calcitonin measurement in pediatrics: reference ranges are gender-dependent, validation in medullary thyroid cancer and thyroid diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1242-1250	5.9	7
80	Sensitive homologous radioimmunoassay for human parathyroid hormone to diagnose hypoparathyroid conditions. <i>Annals of Clinical Biochemistry</i> , 1987 , 24 (Pt 6), 608-13	2.2	7
79	Changing concepts in the management of hereditary and sporadic medullary thyroid carcinoma. <i>Endocrinology and Metabolism Clinics of North America</i> , 1990 , 19, 613-35	5.5	7
78	Effects of 17 beta-estradiol on calcitonin secretion and content in a human medullary thyroid carcinoma cell line. <i>Journal of Bone and Mineral Research</i> , 1991 , 6, 1191-5	6.3	6
77	Evaluation of somatostatin as a plasma tumor marker in medullary thyroid carcinoma. <i>Thyroid</i> , 1995 , 5, 287-91	6.2	6
76	Major role of dihydropyridine-sensitive Ca ²⁺ channels in Ca(2+)-induced calcitonin secretion. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1993 , 264, E354-60	6	6

75	Somatostatin inhibits the norepinephrine-activated calcium channels in rMTC 6-23 cells: possible involvement of a pertussis toxin-sensitive G-protein. <i>European Journal of Endocrinology</i> , 1992 , 127, 378-84	6.5	6
74	Different effects of hypercalcemic state induced by Walker tumor (HWCS 256) and 1,25 (OH)D3 intoxication on rat thyroid C cells. An ultrastructural, immunocytochemical, and biochemical study. <i>Histochemistry</i> , 1984 , 80, 503-8		6
73	Procalcitonin measured by three different assays is an excellent tumor marker for the follow-up of patients with medullary thyroid carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, 1861-1868	5.8	6
72	Diminished calcitonin secretion after ovariectomy without apparent reduction in calcitonin content in the rat. <i>Hormone and Metabolic Research</i> , 1993 , 25, 389-90	3.1	5
71	Homologous desensitization of calcitonin receptors and calcitonin-dependent adenylate cyclase in T47D cells. <i>European Journal of Endocrinology</i> , 1993 , 128, 373-8	6.5	5
70	Internalization of calcitonin receptors in primary rat kidney cell cultures. <i>European Journal of Endocrinology</i> , 1990 , 122, 255-62	6.5	5
69	Drug therapy of hypercalcemia due to malignancy. <i>Recent Results in Cancer Research</i> , 1994 , 137, 138-60	1.5	5
68	Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	4
67	Clinical utility gene card for: multiple endocrine neoplasia type 2. <i>European Journal of Human Genetics</i> , 2012 , 20,	5.3	4
66	Long-term exposure to SMS 201-995 inhibits proliferation and calcitonin release in neoplastic C-cells. <i>Hormone and Metabolic Research</i> , 1993 , 25, 528-31	3.1	4
65	Development and validation of an assay to measure bioactivity of human calcitonin in vitro using T47D cell membranes. <i>Analytical Biochemistry</i> , 1993 , 212, 91-7	3.1	4
64	Secretion of calcitonin and carcinoembryonic antigen in long-term organ culture of human medullary thyroid carcinoma: biochemical and immunocytochemical studies. <i>Klinische Wochenschrift</i> , 1985 , 63, 205-10		4
63	Similar Stage-dependent Survival and Outcome in Sporadic and Hereditary Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e3582-e3591	5.6	4
62	Late diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2006 , 114, 208-14	2.3	3
61	Adenosine A1-receptors inhibit cAMP and Ca ²⁺ mediated calcitonin secretion in C-cells. <i>Hormone and Metabolic Research</i> , 1995 , 27, 408-14	3.1	3
60	In vitro secretion of calcitonin from a rat C cell line: effect of repetitive stimulation with the calcium channel agonist BAY K 8644. <i>Hormone and Metabolic Research</i> , 1992 , 24, 272-5	3.1	3
59	Procollagen-III peptide serum levels in Paget disease of the bone. <i>Klinische Wochenschrift</i> , 1987 , 65, 174-8		3
58	Pheochromocytoma in multiple endocrine neoplasia. <i>Cardiology</i> , 1985 , 72 Suppl 1, 147-9	1.6	3

57	In vitro secretion of peptides of the calcitonin family: calcitonin, katacalcin, and calcitonin gene-related peptide. <i>Henry Ford Hospital Medical Journal</i> , 1987 , 35, 143-6		3
56	Regulation of calcitonin secretion and calcitonin gene expression. <i>Recent Results in Cancer Research</i> , 1992 , 125, 1-18	1.5	3
55	A Novel Mutation of the Calcium Sensing Receptor Gene in a Franconian Kindred: Heterozygous Mutation c.1697_1698delTG Exon 6. <i>Hormone and Metabolic Research</i> , 2017 , 49, 142-146	3.1	2
54	Relapsing pheochromocytoma in a Chinese women caused by a novel mutation in exon 6 of the SDHB gene: a case report. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007 , 115, 616-8	2.3	2
53	Crucial role of c-myc in 1,25(OH)2D3 control of C-cell-carcinoma proliferation. <i>Biochemical and Biophysical Research Communications</i> , 1995 , 213, 922-7	3.4	2
52	Dynamics of osteoclasia in rats with Walker tumor. <i>Calcified Tissue Research</i> , 1977 , 22 Suppl, 368-70		2
51	Age-Related Association of Calcitonin with Parameters of Anthropometry, Bone and Calcium Metabolism during Childhood. <i>Hormone Research in Paediatrics</i> , 2020 , 93, 361-370	3.3	2
50	Postsurgical follow-up and management. <i>Recent Results in Cancer Research</i> , 1992 , 125, 197-211	1.5	2
49	Multiple Endocrine Neoplasia Type 2		2
48	Medulläres Schilddrüsenkarzinom 2006 , 4071-4091		2
47	Prophylactic thyroidectomy in multiple endocrine neoplasia type 2. <i>Expert Review of Endocrinology and Metabolism</i> , 2010 , 5, 867-874	4.1	1
46	Biochemical parameters in diagnosis and follow-up of patients with multiple endocrine neoplasia type 2. <i>Acta Chirurgica Austriaca</i> , 1997 , 29, 9-11		1
45	Diagnostik des Schilddrüsenkarzinoms. <i>Onkologe</i> , 2005 , 11, 50-57	0.1	1
44	Surgical Therapy and Prognostic Factors in Medullary Thyroid Carcinoma (MTC). Current Evaluation of the German MTC Study Group. <i>Oncology Research and Treatment</i> , 1994 , 17, 594-599	2.8	1
43	Determination of serum calcitonin by immunometric two-site assays in normal subjects and patients with medullary thyroid carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 1992 , 30, 831-5	5.9	1
42	Metastatic C-cell carcinoma: calcitonin and CEA production in monolayer culture. <i>Journal of Cancer Research and Clinical Oncology</i> , 1986 , 111, 284-8	4.9	1
41	Measurement of free cytosolic calcium in single cells: method and application. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 1992 , 14, 327-32		1
40	Medullary thyroid cancer with ectopic Cushing's syndrome: A multicentre case series. <i>Clinical Endocrinology</i> , 2021 ,	3.4	1

39	Diagnosis of Medullary Thyroid Cancer 2005 , 297-309		1
38	Endocrine aspects of medullary thyroid carcinoma. <i>Recent Results in Cancer Research</i> , 1990 , 118, 64-9	1.5	1
37	Diagnosis of Medullary Thyroid Cancer 2001 , 239-249		1
36	Nebenschilddr�sencarcinom und medull�es Schilddr�sencarcinom 1987 , 83-92		1
35	Screening for MEN 2 with biochemical and genetic markers. <i>Recent Results in Cancer Research</i> , 1992 , 125, 105-23	1.5	1
34	CT- and ultrasound-characteristics of hepatic lesions in patients with multiple endocrine neoplasia syndrome. A retrospective image review of 25 cases. <i>PLoS ONE</i> , 2019 , 14, e0212865	3.7	0
33	Calcitonin Screening in Nodular Goiter-Upper Limits. <i>Deutsches A&#x0308;rzteblatt International</i> , 2018 , 115, 221	2.5	0
32	Management des fortgeschrittenen medull�en Schilddr�senkarzinoms. <i>Onkologe</i> , 2014 , 20, 591-598	0.1	0
31	Multiple endokrine Neoplasie Typ 2 und medull�es Schilddr�senkarzinom. <i>Monatsschrift Fur Kinderheilkunde</i> , 2008 , 156, 981-986	0.2	0
30	Asymptomatic primary hyperparathyroidism--need to treat?. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2000 , 108, 247-8	2.3	0
29	Molecular Genetics of MEN2-Related Neuroendocrine Tumours 2017 , 65-81		
28	Risk-stratified follow-up of patients with medullary thyroid carcinoma. <i>International Journal of Endocrine Oncology</i> , 2015 , 2, 249-252	0.3	
27	Familie hypocalciurische Hypercalc�mie �aktuelle Diagnostik und Therapie 2019. <i>Journal F�r Mineralstoffwechsel & Muskuloskelettale Erkrankungen</i> , 2019 , 26, 44-49	0.1	
26	Medull�es Schilddr�senkarzinom. <i>Onkologe</i> , 2019 , 25, 573-579	0.1	
25	The Calcium-Sensing Receptor: Physiology and Pathophysiology 2012 , 69-90		
24	Autoimmunthyreopathien in der Schwangerschaft. <i>Geburtshilfe Und Frauenheilkunde</i> , 2005 , 65, 744-750	2	
23	Bisphosphonate. <i>Der Gynakologe</i> , 1999 , 32, 902-909	0.1	
22	Mutations in the RET Proto-Oncogene in German Families with Multiple Endocrine Neoplasia Type 2 1996 , 119-121		

21 Asymptomatischer primärer Hyperparathyreoidismus: pro Verlaufsbeobachtung. *Acta Chirurgica Austriaca*, **1992**, 24, 70-72

20 Inherited thyroxine-binding globulin excess. Study in a kindred. *Experimental and Clinical Endocrinology and Diabetes*, **1986**, 88, 237-41

2.3

19 120. Therapeutische Aspekte und Möglichkeiten beim Rezidiv des C-Zell-Carcinoms der Schilddrüse. *Konstr Masch Appar Geraetebau*, **1985**, 366, 590-590

18 The calcitonin receptor: characterization and processing. *Progress in Clinical and Biological Research*, **1990**, 332, 67-79

17 Sporadisches und hereditäres medulläres Schilddrüsenkarzinom [Klinik und Diagnostik. *Langenbecks Archiv Fu r Chirurgie Supplement*, **2000**, 344-349

16 Hyper- und Hypoparathyreoidismus **2001**, 111-136

15 Multiple Endocrine Neoplasia Type 21-8

14 Primärer Hyperparathyreoidismus [Internistische Therapie **2019**, 429-432

13 Hypoparathyreoidismus **2019**, 433-435

12 Tumormarker beim C-Zellkarzinom der Schilddrüse: Katakalin, Kalzitinin, Kalzitoningene-related-peptide und karzinoembryonales Antigen **1987**, 258-259

11 Diagnostic Value of the Peptides from the Calcitonin Gene **1990**, 48-59

10 Tumorbedingte Hyperkalzämie. Therapie mit Bisphosphonaten. *Innovative Aspekte Der Klinischen Medizin*, **1992**, 93-97

9 In vitro-Bioassays für humanes Calcitonin. *Ersatz- Und Ergänzungsmethoden Zu Tierversuchen*, **1993**, 198-204

8 Spezifische ret proto-onkogen Mutationen bei verschiedenen hereditären Formen des C-Zell-Karzinoms **1995**, 303-306

7 Medulläres Schilddrüsenkarzinom **1997**, 914-930

6 Einfluß der primären chirurgischen Therapie auf den Verlauf des C-Zell-Karzinoms der Schilddrüse **1998**, 1041-1043

5 Primärer Hyperparathyreoidismus **2010**, 289-296

4 Multiple endokrine Neoplasie **2010**, 475-483

- 3 Postersession I. *Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin*, **1984**, 1207-1247
- 2 Multiple endokrine Neoplasie. *Onkologie Up2date*, **2020**, 2, 19-29 ○
- 1 Molekulargenetische Diagnostik beim medullären Schilddrüsenkarzinom. *Chinese Journal of Polymer Science (English Edition)*, **2016**, 39, 120-123 ○.1